Shenzhen Weiguang Biological Products002880.SZValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Deeply Undervalued” zone.
As of Oct 19, 2026, Shenzhen Weiguang Biological Products (002880.SZ) trades at a P/E of 25.60x, P/B of 1.95x, P/S of 5.21x, and a dividend yield of 0.97%.
Longitudinal percentile comparison: P/E sits at the 12th percentile over the trailing 10Y window (vs. 36th percentile over 3Y); P/B sits at the 2nd percentile over the trailing 10Y window (vs. 6th percentile over 3Y); P/S sits at the 6th percentile over the trailing 10Y window (vs. 18th percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 32nd percentile within its industry and the 35th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 0.97%, ranking at the 80th percentile over the trailing 20Y window.
Cross-checking P/E against P/B, the two percentiles sit within 10.2 points of each other — a consistent signal from both angles. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. Shenzhen Weiguang Biological Products operates in the Medicine sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: SHE: 002880 · SZSE: 002880 · 002880
Want the full picture on whether Shenzhen Weiguang Biological Products (002880.SZ) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 25.60 | ||||||
| P/B (MRQ) | 1.95 | ||||||
| P/S (TTM) | 5.21 | ||||||
| Dividend Yield | 0.97% | ||||||
| Buyback + Div Yield | 0.97% |